PortfoliosLab logoPortfoliosLab logo
PRME vs. CRBP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PRME vs. CRBP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PRME achieves a -2.88% return, which is significantly lower than CRBP's 2.09% return.


PRME

1D
4.33%
1M
13.47%
YTD
-2.88%
6M
-8.92%
1Y
62.80%
3Y*
-39.21%
5Y*
10Y*

CRBP

1D
0.61%
1M
-26.78%
YTD
2.09%
6M
-0.36%
1Y
0.85%
3Y*
-1.85%
5Y*
-32.59%
10Y*
-21.17%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PRME vs. CRBP - Yearly Performance Comparison


2026 (YTD)2025202420232022
PRME
Prime Medicine Inc. Common Stock
-2.88%18.84%-67.04%-52.31%-2.06%
CRBP
Corbus Pharmaceuticals Holdings, Inc.
2.09%-31.02%95.36%82.20%-1.34%

Correlation

The correlation between PRME and CRBP is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.21

Correlation (3Y)
Calculated over the trailing 3-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Oct 20, 2022

0.22

Fundamentals

Market Cap

PRME:

$596.81M

CRBP:

$155.45M

EPS

PRME:

-$1.29

CRBP:

-$5.98

PB Ratio

PRME:

7.78

CRBP:

1.23

Total Revenue (TTM)

PRME:

$3.18M

CRBP:

$0.00

Gross Profit (TTM)

PRME:

-$4.14M

CRBP:

-$149.00K

EBITDA (TTM)

PRME:

-$195.72M

CRBP:

-$61.36M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PRME vs. CRBP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME
PRME Risk / Return Rank: 6464
Overall Rank
PRME Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
PRME Sortino Ratio Rank: 6969
Sortino Ratio Rank
PRME Omega Ratio Rank: 6363
Omega Ratio Rank
PRME Calmar Ratio Rank: 6464
Calmar Ratio Rank
PRME Martin Ratio Rank: 5959
Martin Ratio Rank

CRBP
CRBP Risk / Return Rank: 4444
Overall Rank
CRBP Sharpe Ratio Rank: 4343
Sharpe Ratio Rank
CRBP Sortino Ratio Rank: 4646
Sortino Ratio Rank
CRBP Omega Ratio Rank: 4747
Omega Ratio Rank
CRBP Calmar Ratio Rank: 4242
Calmar Ratio Rank
CRBP Martin Ratio Rank: 4242
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRME vs. CRBP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PRMECRBPDifference
Sharpe ratioReturn per unit of total volatility

+0.65

Sortino ratioReturn per unit of downside risk

+1.03

Omega ratioGain probability vs. loss probability

1.17

1.09

+0.08

Calmar ratioReturn relative to maximum drawdown

1.06

0.01

+1.05

Martin ratioReturn relative to average drawdown

1.66

0.02

+1.64

PRME vs. CRBP - Sharpe Ratio Comparison

The current PRME Sharpe Ratio is 0.66, which is higher than the CRBP Sharpe Ratio of 0.01. The chart below compares the historical Sharpe Ratios of PRME and CRBP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PRME vs. CRBP - Drawdown Comparison

The maximum PRME drawdown since its inception was -94.55%, roughly equal to the maximum CRBP drawdown of -99.31%. Use the drawdown chart below to compare losses from any high point for PRME and CRBP.


Loading charts...

Drawdown Indicators


PRMECRBPDifference

Max Drawdown

Largest peak-to-trough decline

-94.55%

-99.31%

+4.76%

Max Drawdown (1Y)

Largest decline over 1 year

-59.52%

-61.88%

+2.36%

Max Drawdown (3Y)

Largest decline over 3 years

-92.37%

-92.01%

-0.36%

Max Drawdown (5Y)

Largest decline over 5 years

-96.55%

Max Drawdown (10Y)

Largest decline over 10 years

-99.31%

Current Drawdown

Current decline from peak

-84.04%

-97.32%

+13.28%

Average Drawdown

Average peak-to-trough decline

-65.61%

-66.11%

+0.50%

Ulcer Index

Depth and duration of drawdowns from previous peaks

38.02%

41.86%

-3.84%

Volatility

PRME vs. CRBP - Volatility Comparison

The current volatility for Prime Medicine Inc. Common Stock (PRME) is 26.45%, while Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a volatility of 43.31%. This indicates that PRME experiences smaller price fluctuations and is considered to be less risky than CRBP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PRMECRBPDifference

Volatility (1M)

Calculated over the trailing 1-month period

26.45%

43.31%

-16.86%

Volatility (6M)

Calculated over the trailing 6-month period

53.90%

60.26%

-6.36%

Volatility (1Y)

Calculated over the trailing 1-year period

96.08%

81.71%

+14.37%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

90.38%

159.23%

-68.85%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

90.38%

129.12%

-38.74%

Dividends

PRME vs. CRBP - Dividend Comparison

Neither PRME nor CRBP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PRME vs. CRBP - Financials Comparison

This section allows you to compare key financial metrics between Prime Medicine Inc. Common Stock and Corbus Pharmaceuticals Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00K1.00M1.50M2.00M2022202320242025202600
(PRME) Total Revenue
(CRBP) Total Revenue
Values in USD except per share items

Frequently Asked Questions


PRME and CRBP have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRBP has higher volatility (43.31%) compared to PRME (26.45%). In terms of maximum drawdown, PRME dropped -94.55% vs CRBP's -99.31%.

PRME currently has the higher Sharpe Ratio (0.66 vs 0.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PRME and CRBP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer